Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

29.71
+0.24000.81%
Pre-market: 30.130.4200+1.41%05:06 EST
Volume:1.33M
Turnover:39.71M
Market Cap:2.66B
PE:-29.27
High:30.65
Open:29.91
Low:29.45
Close:29.47
52wk High:42.13
52wk Low:12.91
Shares:89.47M
Float Shares:79.29M
Volume Ratio:0.79
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0152
EPS(LYR):-4.0759
ROE:-410.78%
ROA:-10.75%
PB:36.13
PE(LYR):-7.29

Loading ...

Travere Therapeutics präsentiert sich auf dem Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 05

Travere Therapeutics (TVTX) Faces FILSPARI Delay and Legal Scrutiny Is Execution Risk Repricing Ahead?

Simply Wall St.
·
Jan 30

Travere Therapeutics CEO Eric M. Dube Reports Disposal of Common Shares

Reuters
·
Jan 28

H.C. Wainwright Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
Jan 28

Assessing Travere Therapeutics (TVTX) Valuation As FDA Extends FILSPARI Review For FSGS Approval

Simply Wall St.
·
Jan 26

Chief Legal Officer Elizabeth E. Reed Reports Disposal of Travere Therapeutics Inc. Common Shares

Reuters
·
Jan 22

Travere Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jan 22

Travere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation

Reuters
·
Jan 17

Stock Track | Travere Therapeutics Plummets 5.43% Intraday as FDA Delays Review of Key Kidney Drug

Stock Track
·
Jan 14

Wedbush Remains a Buy on Travere Therapeutics (TVTX)

TIPRANKS
·
Jan 14

Guggenheim Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
Jan 14

Travere Stock Slips After FDA Delays Review Of Key Kidney Drug

Benzinga
·
Jan 14

Leerink says Travere’s Filspari PDUFA extension removes worst case scenario

TIPRANKS
·
Jan 14

Why Is Travere Therapeutics Stock (TVTX) Tumbling Today?

TIPRANKS
·
Jan 14

Travere Therapeutics announces FDA extends review of FILSPARI sNDA

TIPRANKS
·
Jan 14

US FDA extends review of Travere’s drug for rare kidney disease

Reuters
·
Jan 14

BRIEF-Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS

Reuters
·
Jan 14

Travere Therapeutics Inc - New Pdufa Target Action Date Set for April 13, 2026

THOMSON REUTERS
·
Jan 14

Travere Therapeutics Inc - No Additional Safety or Manufacturing Info Requested for Filspari

THOMSON REUTERS
·
Jan 14

Travere Therapeutics Announces FDA Extends Review of Snda for Filspari® (Sparsentan) in Fsgs

THOMSON REUTERS
·
Jan 14